NCT01925989View on ClinicalTrials.gov

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Type 1 Diabetes Mellitus
Interventions
BIOLOGICAL

LY2605541

Administered SQ

BIOLOGICAL

Insulin Glargine

Administered SQ

Trial Locations (1)

32804

Translational Research Institute for Metabolism and Diabetes, Orlando

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01925989 - A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics | Biotech Hunter | Biotech Hunter